Shopping Cart
Remove All
Your shopping cart is currently empty
Eltanexor (ONO-7706) is an orally active exportin-1 (XPO1) inhibitor. It has effective anti-leukemic activity. Eltanexor inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor causes caspase-dependent apoptosis in a panel of leukemic cell lines.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $60 | In Stock | In Stock | |
| 5 mg | $237 | In Stock | In Stock | |
| 10 mg | $278 | In Stock | In Stock | |
| 25 mg | $448 | In Stock | In Stock | |
| 50 mg | $662 | In Stock | In Stock | |
| 100 mg | $959 | In Stock | In Stock | |
| 200 mg | $1,290 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $223 | In Stock | In Stock |
| Description | Eltanexor (ONO-7706) is an orally active exportin-1 (XPO1) inhibitor. It has effective anti-leukemic activity. Eltanexor inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor causes caspase-dependent apoptosis in a panel of leukemic cell lines. |
| Targets&IC50 | XPO1:60.9 nM(EC50) |
| In vitro | Eltanexor (KPT-8602) (1 nM; 16 hours) causes apoptosis in leukemia cell lines. KPT-8602 (2-6 nM; 72 hours) decreases cell viability in leukemia cell lines (EC50s ranging from 25 to 145 nM). |
| In vivo | KPT-8602 (15 mg/kg; oral gavage; daily for 12 days) demonstrates potent anti-lymphoblastic leukemia activity. |
| Synonyms | ONO-7706, KPT-8602, ATG-016 |
| Molecular Weight | 428.29 |
| Formula | C17H10F6N6O |
| Cas No. | 1642300-52-4 |
| Smiles | NC(=O)C(=C\n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1 |
| Relative Density. | 1.57 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (186.79 mM), Sonication is recommended. H2O: < 0.1 mg/mL (insoluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.